Natco Pharma Share Price
NATCOPHARM
Live Natco Pharma Share Price Chart
Natco Pharma Performance
Days Range
| Previous Close | ₹898.35 |
|---|---|
| Open | ₹898.95 |
| Volume | 3,17,991 |
| Day's Range | ₹886.00 - ₹916.00 |
|---|---|
| 52W Range | ₹789.00 - ₹1,226.80 |
| Market Cap | ₹16,080.48 Cr |
Natco Pharma Fundamentals
| ROCE(TTM) | 15.37 |
|---|---|
| P/E Ratio (TTM) | 14.05 |
| P/B Ratio | 1.74 |
| Industry P/E | 37.30 |
| Debt to Equity | 0.08 |
| ROE | 15.38 |
| EPS (TTM) | 63.89 |
| Dividend Yield | 0.56 |
| Book Value | 514.83 |
| Face Value | 2 |
| ROCE(TTM) | 15.37 |
|---|---|
| P/E Ratio (TTM) | 14.05 |
| P/B Ratio | 1.74 |
| Industry P/E | 37.30 |
| Debt to Equity | 0.08 |
| ROE | 15.38 |
|---|---|
| EPS (TTM) | 63.89 |
| Dividend Yield | 0.56 |
| Book Value | 514.83 |
| Face Value | 2 |
Natco Pharma Financials
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Net Sales | 1,363.00 | 647.30 | 739.10 | 735.20 |
| Expenses | 836.20 | 534.80 | 661.90 | 595.80 |
| Profit before tax | 613.70 | 161.10 | 144.10 | 185.60 |
| Operating Profit | 517.90 | 140.40 | 233.30 | 122.20 |
| Net Profit | 517.90 | 140.40 | 233.30 | 122.20 |
| EPS in Rs | 28.94 | 8.46 | 14.96 | 11.53 |
Natco Pharma Shareholding Pattern
Promoters
49.42%
Retail And Others
27.97%
Foreign Institutional Investors
16.99%
Domestic Institutional Investors
5.62%
About Natco Pharma
History of Natco Pharma Limited
Incorporated in 1981, Natco Pharma Limited is involved in the manufacturing and sale of pharmaceutical products. The company was started in 1981 in Kothur, Mahaboobnagar district, Telangana. In 1986, they opened a parental manufacturing unit at Nagarjunasagar. In 1993, the company inaugurated a chemical division at Mekaguda. In 1995, Natco Trust was founded, and Natco merged three of the group companies with the parent company. In the same year, they went public and got listed on the Indian stock exchanges. In 1997, they opened the Natco Research Centre (NRC). In 2003, the company entered the Oncology division and launched its flagship brand, Veenat. In 2006, Natco Pharma Limited established a finished dosage unit at Dehradun. In the next year, i.e., in 2007, they launched their first Abbreviated New Drug Application (ANDA) in the USA. They also acquired Savemart Pharmacy in the USA. In 2009, the company established Natco Organics in Chennai, and in the same year, the company turnover touched $100 million. Between 2013 and 2014, the company established in Canada and Australia. In 2016, Natco Pharma Limited sold Savemart Pharmacy in the USA. In 2017, they entered the Diabetology and Cardiology divisions. In 2018, they launched Teriflunomide, the company’s first generic version of oral tablets for multiple sclerosis in India. In 2019, they launched the crop health science division. In 2020, the company’s Vishakapatnam Formulation unit was approved by the US FDA. In the same year, Natco Pharma supplied COVID-19 treatment tablets, Chloroquine Phosphate tablets in the USA. In 2021, the company launched other drugs for Covid treatment. In 2022, Natco Pharma’s crop health science division launched agro products in India. As of March 2023, Natco Pharma Limited has a presence in more than 50 countries and 465 scientists. They have 5 Finished Dosage Forms (FDF) manufacturing units, 2 Active Pharmaceutical Ingredients (API) manufacturing units, 2 R&D centres and 2 crop health sciences units.Business Segments of Natco Pharma Limited
The two primary business segments of the company are as follows:- Pharmaceuticals: In this segment, the company is involved in the development, manufacturing and marketing of FDF and APIs.
- Agrochemicals: In this segment, the company focuses on providing eco-friendly biopesticide products for farmers, thus contributing to sustainable farming.
- Natco Pharma Inc: This wholly-owned subsidiary of the company is involved in the retail sale of prescription drugs and non-prescription medicines.
- Natco Pharma Australia Pty Ltd: This wholly-owned subsidiary of the company was established for the sale and distribution of pharmaceutical products in Australia.
- Natco Pharma (Canada) Inc: This wholly-owned subsidiary of the company was established for the sale and distribution of pharmaceutical products in Canada.
Key Personalities of Natco Pharma Limited
V.C. Nannapaneni, Managing Director V.C. Nannapaneni is the Managing Director of Natco Pharma Limited. He has more than 40 years of experience in the pharmaceutical sector. In addition to handling general management responsibilities, he supervises the New Drug Discovery program within the company.Parent Organisation
Natco
Managing Director
NA
Founded
1981
NSE Symbol
NATCOPHARM
Top Mutual Funds Invested in Natco Pharma Share
Peer Comparison
| Stocks | LTP (₹) | Market Cap (cr) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 1,898.9 23.80 (1.27%) | ₹4,50,211.21 | 1,548.0 - 2,046.9 |
| Divis Laboratories Ltd | 8,527.0 -61.00 (-0.71%) | ₹2,28,302.98 | 5,636.5 - 8,674.0 |
| Torrent Pharmaceuticals Ltd | 5,015.0 44.00 (0.89%) | ₹1,89,233.01 | 3,480.6 - 5,250.0 |
| Cipla Ltd | 1,422.0 -9.10 (-0.64%) | ₹1,15,672.46 | 1,165.7 - 1,673.0 |
| Zydus Lifesciences Ltd | 1,110.0 -5.60 (-0.50%) | ₹1,11,421.18 | 835.5 - 1,205.0 |
| Lupin Ltd | 2,220.1 -11.90 (-0.53%) | ₹1,01,734.24 | 1,875.0 - 2,529.5 |
Popular Stocks
Natco Pharma Ltd FAQs
Can I buy Natco Pharma Ltd (NATCOPHARM) from Angel One?
Yes, You can buy Natco Pharma Ltd (NATCOPHARM) shares by opening a Demat account with Angel One.
How do I buy Natco Pharma Ltd (NATCOPHARM) from Angel One?
Natco Pharma Ltd (NATCOPHARM) share can be bought through the following modes:
1. Direct investment: You can buy Natco Pharma Ltd (NATCOPHARM) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Natco Pharma Ltd (NATCOPHARM) shares.
1. Direct investment: You can buy Natco Pharma Ltd (NATCOPHARM) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Natco Pharma Ltd (NATCOPHARM) shares.
What is the main business of NATCO Pharma?
The main business of NATCO Pharma is the production and distribution of pharmaceutical products, including generic drugs and active pharmaceutical ingredients (APIs). They also place an emphasis on pharmaceutical research and development.
Who are the promoters of NATCO Pharma?
VC Nannapaneni, Time Cap Pharma Labs Limited, Venkata Satya Swathi Kantamani, Natsoft Information Systems Pvt Ltd are the major promoters of NATCO Pharma.
What are the Subsidiaries that comes under NATCO Pharma?
NATCO Trust, NATCO Organics, and NATCO Biotech are all subsidiaries of NATCO Pharma. These subsidiaries focus on organic chemicals, biotechnology, and healthcare services, respectively.
